Three-Domain Antibacterial Polypeptides for Mycobacterial Cell Walls
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial peptides, such as LysA and LysB, are insufficient to effectively disrupt the complex cell walls of mycobacteria, requiring combination with outer membrane permeabilizers, and fail to target dormant/latent cells, necessitating improved peptides with multiple activities in a single peptide.
Innovation Solution
Development of peptides comprising three domains: one with activity specific to peptidoglycan, one with activity specific to an ester linkage, and one with membrane permeabilizing activity, enabling targeted disruption and killing of mycobacterial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antimicrobial peptides (LysA and LysB) are used, then some antibacterial activity is achieved, but they are insufficient to effectively disrupt the complex cell walls of mycobacteria and require combination with outer membrane permeabilizers
Solution Approach 1:
The patent combines multiple functional domains (peptidoglycan-targeting domain, ester linkage-targeting domain, and membrane permeabilizing domain) into a single polypeptide molecule. This merging of functions allows the polypeptide to effectively disrupt the complex mycobacterial cell wall without requiring combination with additional outer membrane permeabilizers, thereby improving reliability while managing complexity through integrated design
Solution Approach 2:
The invented polypeptide is designed to perform multiple functions simultaneously: it can target peptidoglycan, hydrolyze ester linkages in the cell wall, and permeabilize membranes. This multi-functionality enables a single agent to address multiple barriers in the mycobacterial cell envelope, improving efficacy without requiring multiple separate components
2Adaptability or versatility
If current antimicrobial peptides are used, then active replication cells are targeted, but dormant/latent cells are not effectively targeted
Solution Approach 1:
The polypeptide's multiple functional domains enable it to act on different cell wall components and membrane structures, providing versatility that allows it to target both actively replicating cells and dormant/latent cells with different metabolic states and cell wall compositions
3Reliability
If multiple separate peptides are used to achieve comprehensive antimycobacterial activity, then effective killing is achieved, but the treatment complexity increases
Solution Approach 1:
By consolidating peptidoglycan degradation, ester linkage hydrolysis, and membrane permeabilization functions into a single polypeptide, the invention eliminates the need for complex combination therapies with multiple separate peptides and outer membrane permeabilizers, simplifying the treatment regimen while maintaining comprehensive antimycobacterial activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides exhibit enhanced specificity, selectivity, and faster expression rates, effectively targeting and killing mycobacteria, including dormant/latent cells, with improved inhibitory activity compared to existing combinations.
Implementation Method 1
LysA (peptidoglycan hydrolase enzymes)
Implementation Method 2
LysB (mycolyl arabinogalactan esterase enzymes that are not typically considered as conventional endolysins, but can instead be categorized as enzymes with lipolytic activity) cleaves the ester linkage of mycolic acids to the arabinogalactan layer
Data Source
AI summary
The present invention relates to antimicrobial peptides comprised of a first domain with activity specific to a peptidoglycan or component thereof; a second domain with activity specific to an ester linkage; and a third domain with membrane permeabilising activity. The invention also relates to the use of such peptides in medicine, for example for treating mycobacterial infection.